Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Safety Office Is “Separate, But Unequal,” Senate Committee Says

Executive Summary

A Senate committee investigation into FDA's handling of pediatric suicidality concerns with antidepressant drugs is focusing on the "unequal" status of the Office of Drug Safety and the Office of New Drugs

You may also be interested in...



FDA Office Of Drug Safety Acting Director Is Ralph Lillie

FDA Emergency Preparedness Officer Ralph Lillie is serving as acting director of the Office of Drug Safety in the Center for Drug Evaluation & Research as of Jan. 23

FDA Office Of Drug Safety Acting Director Is Ralph Lillie

FDA Emergency Preparedness Officer Ralph Lillie is serving as acting director of the Office of Drug Safety in the Center for Drug Evaluation & Research as of Jan. 23

Vioxx Hearing May Be Sign Of Things To Come Under Medicare Rx

The Senate Finance Committee should continue to review FDA's drug safety procedures in light of the upcoming expansion of the Medicare program, Ranking Democrat Max Baucus (D-Mont.) maintained during the committee's Nov. 18 hearing on Vioxx

Related Content

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel